SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) JUNE 30, 1995 ENZON, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 0-12957 22-237286 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification)

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") and Schering Corporation, a subsidiary of Schering-Plough Corporation ("Schering"), have further amended (the "Revised Agreement") their November 1990 license and development agreement for PEG-INTRON A (the "Original Agreement"). Under the Revised Agreement, Schering will obtain Enzon's proprietary know-how for PEG-Intron A and acquire manufacturing $% \left(1\right) =\left(1\right) +\left(1\right)$ with respect to manufacturing PEG-Intron A. Enzon has an option to become Schering's exclusive manufacturer of PEG-INTRON A for the U.S. market. Schering will retain exclusive worldwide marketing rights for PEG-INTRON A and continue to be responsible for conducting clinical studies and securing regulatory approval. Enzon is entitled to receive the milestone payments and royalties provided by the Original Agreement. In addition to such milestone payments, Schering paid to Enzon a \$2,000,000 license fee with an additional \$1,000,000 to be paid upon completion of the technology transfer. Last quarter Enzon delivered to Schering two PEG-INTRON A formulations having improved performance characteristics for anticipated clinical trials.

Concurrently with executing the Revised Agreement, Schering purchased 847,849 shares (the "Shares") of Enzon's common stock, \$.01 par value, for aggregate consideration of \$2,000,000. Schering received demand registration rights exercisable no sooner than January 1996 and piggy-back registration rights with respect to the Shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Dated: July 20, 1995

ENZON, INC. (Registrant)

By: /S/ JOHN A. CARUSO John A.

Caruso

Vice President, Business Development and General Counsel